Embargo 13 April – 09:12 CEST
Key takeaways
Heart failure (HF) is prevalent in patients with atrial fibrillation (AF), but limited data exist on the incidence of HF in asymptomatic individuals who have AF detected during screening.
Analyses of the Swedish STROKESTOP and STROKESTOP II studies showed that people with screening-detected AF had a threefold higher risk of developing HF compared with participants without AF and similar risk to those with previously known AF.
These findings suggest that screening-detected AF is not a benign condition and highlight the need for early detection of both AF and HF.
Paris, France – 13 April 2026: Heart failure is common in people who have atrial fibrillation detected during screening, according to a presentation today at EHRA 2026 1 the annual congress of the European Heart Rhythm Association (EHRA) , a branch of the European Society of Cardiology (ESC).
Atrial fibrillation (AF) affects almost 38 million people worldwide, with the prevalence predicted to double over the next 35 years. 2 Stroke is a feared outcome of AF, but heart failure (HF) also occurs frequently in patients with AF and is a major cause of death. 3
“HF and AF have a bidirectional relationship and accelerate each other’s progression , so it is important to identify and treat HF early in patients with AF,” explained Doctor Gina Sado from Danderyd Hospital, Stockholm, Sweden. “HF has been well studied in patients with clinically known AF, but little is known about the incidence and timing of HF in individuals whose AF has been detected during screening.”
In the Swedish STROKESTOP and STROKESTOP II studies, 4,5 individuals aged 75–76 years were randomised to receive ECG-based AF screening or to serve as controls. This post-hoc analysis studied the incidence of new HF diagnosis based on a median follow-up of 6.9 years for STROKESTOP and 5.1 years for STROKESTOP II. Data on HF diagnoses and mortality were obtained from national registries. Cox regression was used to estimate the hazard ratios (HRs) for incident HF across groups.
Out of 6,824 individuals screened in STROKESTOP, new AF was detected in 252 individuals and of these, 57 were diagnosed with HF (23%) over the follow-up period.
Out of 6,601 individuals screened in STROKESTOP II, new AF was detected in 152 individuals and of these, 31 were diagnosed with HF (20%) over the follow-up period.
In STROKESTOP, screening-detected AF was associated with a threefold increased risk of HF compared with individuals without AF (adjusted HR 3.19; 95% confidence intervals [CI] 2.42 to 4.21) and with a comparable HF risk to patients with previously known AF (adjusted HR 2.86; 95% CI 2.34 to 3.50). Similar results were observed in STROKESTOP II.
Notably, HF was diagnosed early, within 6 months after AF detection in both studies and AF groups.
Summing up the results, Doctor Sado concluded: “In individuals with screening-detected AF, the risk of developing HF was threefold that of participants without AF and comparable to that of patients with clinically known AF. These findings suggest that asymptomatic AF is not a benign condition and highlight the need for early detection of both AF and HF.”
ENDS
Notes to Editor
Funding:
STROKESTOP was supported by Stockholm County Council, the Swedish Heart & Lung Foundation, King Gustav V and Queen Victoria's Freemasons' Foundation, the Klebergska Foundation, the Tornspiran Foundation, the Scientific Council of Halland Region, the Southern Regional Healthcare Committee, the Swedish Stroke Fund, Carl Bennet AB, CIMED, Boehringer Ingelheim, Bayer, Bristol Myers Squibb and Pfizer.
STROKESTOP II was supported by Roche Diagnostics, Carl Bennet AB, CIMED, Stockholm Region and the Swedish Heart Lung Foundation.
Disclosures: Doctor Sado reports no disclosures related to this study.
References:
[1] ‘Heart failure over time in patients with screening detected atrial fibrillation - a posthoc analysis of the STROKESTOP and STROKESTOP II studies’ presented during the Atrial fibrillation miscellaneous session on 13 April at 08:30 to 09:30 in Room Agora.
[2] Lane DA, Andrade JG, Arbelo E, et al. Atrial fibrillation. Lancet. 2026;407:1000−1013.
[3] Deisenhofer I. Atrial fibrillation in heart failure: Prime time for ablation! Heart Rhythm O2. 2021;2(6Part B):754−761.
[4] Svennberg E, Friberg L, Frykman V, et al. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet. 2021;398:1498−1506.
[5] Kemp Gudmundsdottir K, Fredriksson T, Svennberg E, et al. Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study. Europace 2020;22:24–32.
ESC Press Office
Tel: +33 6 61 40 18 84
Email: press@escardio.org
Follow European Society of Cardiology News on LinkedIn
About the European Society of Cardiology
The ESC brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.
About the European Heart Rhythm Association (EHRA)
The ESC’s European Heart Rhythm Association (EHRA) is a community of more than 4,300 members from around the globe, including physicians, arrhythmologists, young electrophysiologists, nurses and allied professionals. EHRA’s mission is to predict, diagnose and treat heart rhythm disturbances to improve quality of life and outcomes.
EHRA 2026 takes place from 12–14 April at Palais des Congrès, Paris, France. Explore the scientific programme.
Free registration applies to accredited press .
Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles. Read the ESC media and embargo policy .
The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid.
The ESC Press Office decision is final regarding all press registration requests.